Do you try to incorporate mFOLFIRINOX in total neoadjuvant therapy for rectal cancer?

Given the published results of the PRODIGE 23 trial where FOLFORINOX was used neoadjuvantly with FOLFOX post-op

Answer from: Medical Oncologist at Academic Institution

PRODIGE 23 study is an open-label, randomized phase 3 study (Conroy et al., PMID 33862000). Locally advanced rectal cancer patients (cT3 or cT4 M0) were randomized to either the study arm (mFOLFIRINOX X 3 months, chemoradiation, TME, FOLFOX X 3 months) or the standard arm (chemoradiation follow...

Comments

Medical Oncologist at NYU Long Island School of Medicine
Agreed and I would also recommend looking into ref...

Answer from: Medical Oncologist at Academic Institution

Dr. @Jin's answer is very reasonable. In general, we do not routinely utilize mFOLFIRINOX as part of TNT at our center. At this point, it is not clear if intensification of consolidation chemotherapy with the addition of irinotecan in TNT improves rates of cCR compared to standard FOLFOX/CAPOX. This...

Please select the option that best describes you:

Do you try to incorporate mFOLFIRINOX in total neoadjuvant therapy for rectal cancer?

Related Questions